{"id":"iti","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immunosuppression-related complications"},{"rate":null,"effect":"Thrombosis"}]},"_chembl":null,"_dailymed":{"setId":"6afa8056-1b7a-48a4-960c-92927169977e","title":"WAL-ITIN (LORATADINE) TABLET [WALGREENS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ITI works by suppressing the immune system's response to factor VIII through a regimen typically involving factor VIII infusions combined with immunosuppressive drugs (such as cyclophosphamide and corticosteroids). The goal is to eliminate or reduce factor VIII inhibitor antibodies, allowing patients to safely use factor VIII replacement therapy again. This approach aims to restore immune tolerance rather than simply managing inhibitor levels.","oneSentence":"ITI is an immune tolerance induction therapy that uses a combination of immunosuppressive agents to induce tolerance to factor VIII in hemophilia A patients with inhibitors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:57.022Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A with factor VIII inhibitors"}]},"trialDetails":[{"nctId":"NCT04846517","phase":"NA","title":"rTMS for Aneroxia Nervosa in Youth","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2028-01-30","conditions":"Anorexia Nervosa","enrollment":45},{"nctId":"NCT07366242","phase":"","title":"Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","status":"NOT_YET_RECRUITING","sponsor":"Heba Ahmed Mohamed","startDate":"2026-06-01","conditions":"HGSOC","enrollment":72},{"nctId":"NCT07180654","phase":"","title":"Menstrual Cycle TMS Plasticity Pilot","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-12-15","conditions":"Cortical Activation","enrollment":100},{"nctId":"NCT05322239","phase":"NA","title":"Resting State Changes Following Theta Burst Stimulation","status":"RECRUITING","sponsor":"Nicholas Balderston, PhD","startDate":"2022-11-17","conditions":"Brain Connectivity","enrollment":200},{"nctId":"NCT05611502","phase":"NA","title":"Influence of TMS on Attention Modulation","status":"RECRUITING","sponsor":"Auburn University","startDate":"2022-08-11","conditions":"Drinking, Alcohol","enrollment":40},{"nctId":"NCT05621538","phase":"NA","title":"A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder","status":"RECRUITING","sponsor":"Auburn University","startDate":"2025-10-01","conditions":"Alcohol Use Disorder","enrollment":90},{"nctId":"NCT06475274","phase":"PHASE2","title":"A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery","status":"COMPLETED","sponsor":"Guard Therapeutics AB","startDate":"2024-08-26","conditions":"Kidney Injury Following Open-Chest Cardiac Surgery","enrollment":170},{"nctId":"NCT05732194","phase":"PHASE1","title":"Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2023-01-18","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07158606","phase":"PHASE4","title":"Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction","status":"NOT_YET_RECRUITING","sponsor":"Versiti Blood Health","startDate":"2025-10-01","conditions":"Hemophilia A With Inhibitor","enrollment":15},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT06968026","phase":"NA","title":"Effects of High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomic Regulation in Women With Recurrent Pregnancy Loss and Anxiety: A Proof-of-Concept rTMS-ECG Clinical Trial ( NEURO-CARD)","status":"RECRUITING","sponsor":"Shenyang Jinghua Hospital","startDate":"2025-05-16","conditions":"Recurrent Pregnancy Loss, Anxiety Disorders","enrollment":55},{"nctId":"NCT02615691","phase":"PHASE3","title":"A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-12","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT07065539","phase":"NA","title":"GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-07-20","conditions":"Adenomyosis of Uterus, Frozen Embryo Transfer (FET)","enrollment":432},{"nctId":"NCT03908177","phase":"NA","title":"Comparison of Clinical Performance and Safety of Zirconia vs. Titanium Implants: a Multi-national RCT.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Straumann AG","startDate":"2019-09-07","conditions":"Dental Implants, Single-Tooth","enrollment":124},{"nctId":"NCT04907357","phase":"NA","title":"rTMS for Stimulant Use Disorders","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2022-02-04","conditions":"Cocaine Use Disorder, Methamphetamine Abuse, Cocaine Dependence","enrollment":129},{"nctId":"NCT06998810","phase":"NA","title":"Cerebellar High-Frequency rTMS in Balance of Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-02-25","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT06964243","phase":"NA","title":"Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain","status":"RECRUITING","sponsor":"Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)","startDate":"2025-04-01","conditions":"Chronic Pain Syndrome, Peripheral Neuropathic Pain","enrollment":36},{"nctId":"NCT01665326","phase":"","title":"Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease","status":"RECRUITING","sponsor":"Duke University","startDate":"2009-09","conditions":"Pompe Disease","enrollment":400},{"nctId":"NCT06864975","phase":"PHASE4","title":"Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)","status":"RECRUITING","sponsor":"Runhui WU","startDate":"2025-03-01","conditions":"Hemophilia a with Inhibitor","enrollment":110},{"nctId":"NCT06848127","phase":"NA","title":"Study of Emotional Dysregulation in Complex Post-Traumatic Stress Disorder","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-03-01","conditions":"Complex Post-Traumatic Stress Disorder (CPTSD), Borderline Personality Disorder (BPD), Post-traumatic Stress Disorder (PTSD)","enrollment":170},{"nctId":"NCT05888870","phase":"PHASE4","title":"ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-22","conditions":"Hemophilia A With Inhibitor","enrollment":50},{"nctId":"NCT03993509","phase":"NA","title":"Effect of rTMS on Anxiety","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-10-30","conditions":"Anxiety, Fear, Anxiety and Fear","enrollment":68},{"nctId":"NCT05967416","phase":"PHASE1","title":"Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"SIRPant Immunotherapeutics, Inc.","startDate":"2024-01-17","conditions":"Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT02207894","phase":"","title":"A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI","status":"RECRUITING","sponsor":"Haemophilia Centre Rhine Main","startDate":"2006-08","conditions":"Haemophilia A","enrollment":300},{"nctId":"NCT03951103","phase":"","title":"rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2018-11-07","conditions":"Hemophilia A With Inhibitor","enrollment":44},{"nctId":"NCT03103542","phase":"PHASE4","title":"Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-08-29","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT03984890","phase":"PHASE2, PHASE3","title":"Vitamin D3 For CGD Patients With BCGosis/Itis","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2019-08-01","conditions":"Vitamin D3, Chronic-granulomatous Disease, BCG","enrollment":50},{"nctId":"NCT04308642","phase":"","title":"Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-10-22","conditions":"Kidney Impairment","enrollment":6},{"nctId":"NCT05559463","phase":"NA","title":"Effect of Anti-inflammatory (ITIS) Diet in Knee Osteoarthritis","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-10-01","conditions":"Osteoarthritis, Knee","enrollment":30},{"nctId":"NCT05634759","phase":"PHASE4","title":"Enhancing the A in SAFE for Trachoma","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-05-04","conditions":"Trachoma","enrollment":34630},{"nctId":"NCT04030052","phase":"PHASE3","title":"Emicizumab PUPs and Nuwiq ITI Study","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2022-02-17","conditions":"Hemophilia A","enrollment":""},{"nctId":"NCT06171438","phase":"","title":"Molecular Markers of Acute Kidney Injury in Elderly Deceased Donors","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2021-06-11","conditions":"Kidney Transplantation, Acute Kidney Injury","enrollment":200},{"nctId":"NCT01311648","phase":"PHASE3","title":"BAY81-8973 Pediatric Safety and Efficacy Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-06-09","conditions":"Haemophilia A","enrollment":94},{"nctId":"NCT05326880","phase":"NA","title":"5-year Follow up Study on the Comparative Performance of Two-piece Zirconia and Titanium Implants","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-03","conditions":"Dental Implants, Single Tooth Lost, Dental Implant Failed","enrollment":60},{"nctId":"NCT04226456","phase":"PHASE4","title":"Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2021-07-10","conditions":"Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral, Ototoxicity","enrollment":19},{"nctId":"NCT04621916","phase":"PHASE4","title":"Preventing Inhibitor Recurrence Indefinitely","status":"UNKNOWN","sponsor":"Children's Hospital Los Angeles","startDate":"2020-09-21","conditions":"Hemophilia A, Immune Tolerance","enrollment":52},{"nctId":"NCT02223767","phase":"NA","title":"TMS Augmented Exposure Therapy","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2014-08","conditions":"Phobia","enrollment":47},{"nctId":"NCT05802836","phase":"","title":"Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab","status":"RECRUITING","sponsor":"Christoph Königs","startDate":"2023-04-26","conditions":"Severe Hemophilia A, Severe Hemophilia A With Inhibitor, Severe Hemophilia A Without Inhibitor","enrollment":100},{"nctId":"NCT03973580","phase":"NA","title":"Using Attention Training to Reduce Adolescents' Anxious Symptoms","status":"TERMINATED","sponsor":"Western University, Canada","startDate":"2019-07-29","conditions":"Attentional Bias, Anxiety","enrollment":15},{"nctId":"NCT04934124","phase":"PHASE1","title":"Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers","status":"COMPLETED","sponsor":"Intra-Cellular Therapies, Inc.","startDate":"2020-12-23","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04303572","phase":"PHASE3","title":"The Hemophilia Inhibitor Eradication Trial","status":"TERMINATED","sponsor":"Margaret Ragni","startDate":"2021-11-01","conditions":"Hemophilia A With Inhibitor","enrollment":1},{"nctId":"NCT04086654","phase":"NA","title":"Psychometric Properties of the International Trauma Interview (ITI) for ICD-11 PTSD and CPTSD","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2020-03-02","conditions":"Post Traumatic Stress Disorder (PTSD), Complex Post-Traumatic Stress Disorder (CPTSD)","enrollment":77},{"nctId":"NCT04999683","phase":"NA","title":"Effect of Anti-inflammatory (ITIS) Diet in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-09-01","conditions":"Rheumatoid Arthritis, Osteoarthritis","enrollment":26},{"nctId":"NCT05353231","phase":"NA","title":"Brief Mental Training and Internal Attentional Control","status":"UNKNOWN","sponsor":"University of Haifa","startDate":"2022-05-23","conditions":"Attention Impaired, Mental Health Issue, Rumination","enrollment":90},{"nctId":"NCT02234323","phase":"PHASE3","title":"An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2015-01-12","conditions":"Hemophilia A","enrollment":108},{"nctId":"NCT00701701","phase":"PHASE4","title":"Immune Tolerance Induction Study","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-12-14","conditions":"Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency","enrollment":4},{"nctId":"NCT03093480","phase":"PHASE4","title":"A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2017-12-08","conditions":"Hemophilia A With Inhibitors","enrollment":16},{"nctId":"NCT03095287","phase":"PHASE2","title":"Alphanate in Immune Tolerance Induction Therapy","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2018-01-03","conditions":"Hemophilia A, Congenital","enrollment":2},{"nctId":"NCT01051076","phase":"NA","title":"Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-11-03","conditions":"Severe Hemophilia A","enrollment":3},{"nctId":"NCT00157157","phase":"PHASE3","title":"Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2004-04-01","conditions":"Hemophilia A","enrollment":66},{"nctId":"NCT04554498","phase":"NA","title":"Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2022-01-01","conditions":"Hemodialysis Complication, Inflammation, Uremic; Toxemia","enrollment":16},{"nctId":"NCT04611828","phase":"NA","title":"Slow-wave Enhancement in Adults Aged 30-49","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-09-16","conditions":"Sleep","enrollment":28},{"nctId":"NCT01051544","phase":"NA","title":"Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2009-09-25","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT03204539","phase":"PHASE4","title":"INdividualized ITI Based on Fviii(ATE) Protection by VWF","status":"TERMINATED","sponsor":"University of California, Davis","startDate":"2017-06-01","conditions":"Hemophilia A With Inhibitor, Hemophilia A","enrollment":1},{"nctId":"NCT02196207","phase":"PHASE3","title":"Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform","status":"WITHDRAWN","sponsor":"Margaret Ragni","startDate":"2020-08","conditions":"Severe Hemophilia A","enrollment":""},{"nctId":"NCT03598725","phase":"PHASE4","title":"Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China","status":"UNKNOWN","sponsor":"Beijing Children's Hospital","startDate":"2016-01-01","conditions":"Hemophilia A With Inhibitor","enrollment":55},{"nctId":"NCT02520570","phase":"","title":"Post-market Safety Reassessment of Ulinastatin for Injection","status":"UNKNOWN","sponsor":"Techpool Bio-Pharma Co., Ltd.","startDate":"2014-08","conditions":"Adverse Reaction to Drug","enrollment":10000},{"nctId":"NCT02895191","phase":"PHASE2","title":"The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)","status":"UNKNOWN","sponsor":"Techpool Bio-Pharma Co., Ltd.","startDate":"2016-08","conditions":"Acute Respiratory Distress Syndrome","enrollment":60},{"nctId":"NCT02527811","phase":"PHASE4","title":"Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery","status":"UNKNOWN","sponsor":"Techpool Bio-Pharma Co., Ltd.","startDate":"2015-04","conditions":"Congenital Heart Diseases","enrollment":450},{"nctId":"NCT01132521","phase":"PHASE4","title":"Ulinastatin in Severe Acute Pancreatitis","status":"SUSPENDED","sponsor":"Techpool Bio-Pharma Co., Ltd.","startDate":"2010-06","conditions":"Pancreatitis","enrollment":252},{"nctId":"NCT00616447","phase":"NA","title":"rTMS Treatment in Patients With General Anxiety Disorder","status":"COMPLETED","sponsor":"Queen's University","startDate":"2008-01","conditions":"Generalized Anxiety Disorder","enrollment":30},{"nctId":"NCT01505946","phase":"","title":"Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors","status":"UNKNOWN","sponsor":"Grifols Italia S.p.A","startDate":"2012-03","conditions":"Severe Hemophilia A With Inhibitor","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1982,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"ITI","genericName":"ITI","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"ITI is an immune tolerance induction therapy that uses a combination of immunosuppressive agents to induce tolerance to factor VIII in hemophilia A patients with inhibitors. Used for Hemophilia A with factor VIII inhibitors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}